| ［1］ |
Rowinsky E K.The ErbB family：targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors.Annu Rev Med，2004，55：433-457.
|
| ［2］ |
Yarden Y，Sliwkowski M X.Untangling the ErbB signaling network.Nat Rev Mol Cell Biol，2001，2：127-137.
|
| ［3］ |
Moy B，Goss PE.Lapatinib：current status and future directions in breast cancer.Oncologist，2006，11：1047-1057.
|
| ［4］ |
Herbst R S，Shin D M.Monoclonal antibodies to target epidermal growth factor receptor-positive tumors：a new paradigm for cancer therapy.Cancer，2002，94：1593-1611.
|
| ［5］ |
Nahta R，Hortobágyi GN，Esteva F J.Growth factor receptors in breast cancer：potential for therapeutic intervention.Oncologist，2003，8：5-17.
|
| ［6］ |
Wood E R，Truesdale A T，McDonald O B，et al.A unique structure for epidermal growth receptor bound to GW572016（lapatinib）：relationships among protein conformation，inhibitor off-rate，and receptor activity in tumor cells.Cancer Res，2004，64：6652-6659.
|
| ［7］ |
Xia W，Bisi J，Strum J，et al.Regulation of survivin by ErbB2 signaling：therapeutic implications for ErbB2-overexpressing breast cancers.Cancer Res，2006，66：1640-1647.
|
| ［8］ |
Hegde PS，Rusnak D，Bertiaux M，et al.Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles.Mol Cancer Ther，2007，6：1629-1640.
|
| ［9］ |
Lin N U，Winer E P.New targets for therapy in breast cancer：small molecule tyrosine kinase inhibitors.Breast Cancer Res，2004，6：204-210.
|
| ［10］ |
Sáez R，Molina M A，Ramsey E E，et al.p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer.Clin Cancer Res，2006，12：424-431.
|
| ［11］ |
Xia W，Liu L H，Ho P，et al.Truncated ErbB2 receptor（P95ErbB2）is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.Oncogene，2004，23：646-653.
|
| ［12］ |
Zhou Y，Li S，Hu Y P，et al.Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.Cancer Res，2006，66：404-411.
|
| ［13］ |
Xia W，Mullin R J，Keith B R，et al.Anti-tumor activity of GW572016：a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.Oncogene，2002，21：6255-6263.
|
| ［14］ |
Konecny G E，Pegram M D，Venkatesan N，et al.Activity of the dual kinase inhibitor lapatinib（GW572016）against HER-2-overexpressing and trastuzumab-treated breast cancer cells.Cancer Res，2006，66：1630-1639.
|
| ［15］ |
Zhou H，Kim Y S，Peletier A，et al.Effects of the EGFR/HER-2 kinase inhibitor GW572016 on EGFR-and HER-2-overexpressing breast cancer cell line proliferation，radiosensitization，and resistance.Int JRadiat Oncol Biol Phys，2004，58：344-352.
|
| ［16］ |
Chu I，Blackwell K，Chen S，et al.The Dual ErbB1/ErbB2 inhibitor，lapatinib（GW572016），cooperates with tamoxifen to inhibit both cell proliferation-and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.Cancer Res，2005，65：18-25.
|
| ［17］ |
Bence A K，Anderson E B，Halepota M A，et al.Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016，a dual EGFR-ErbB2 inhibitor，in healthy subjects.Invest New Drugs，2005，23：39-49.
|
| ［18］ |
Burris H A 3rd，Hurwitz H I，Dees E C，et al.PhaseⅠsafety，pharmacokinetics，and clinical activity study of lapatinib（GW572016），a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases，in heavily pretreated patients with metastatic carcinomas.J Clin Oncol，2005，23：5305-5313.
|
| ［19］ |
Cameron D，Casey M，Press M，et al.A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab：updated efficacy and biomarker analyses.Breast Cancer Res Treat，2008，［Epub ahead of print］.
|
| ［20］ |
Moy B，Goss P E.Lapatinib-associated toxicity and practical management recommendations.Oncologist，2007，12：756-765.
|
| ［21］ |
Palmieri D，Smith Q R，Lockman PR，et al.Brain metastases of breast cancer.Breast Dis，2006-2007，26：139-147.
|
| ［22］ |
Lin N U，Dieras V，Paul D，et al.EGF105084，a phase II study of lapatinib for brain metastases in patients（pts）with HER-2＋breast cancer following trastuzumab（H）based systemic therapy and cranial radiotherapy（RT）.JClin Oncol，2007，25：1012.
|
| ［23］ |
Geyer CE，Forster J，Lindquist D，et al.Lapatinib plus capecitabine for HER-2-positive advanced breast cancer.N Engl JMed，2006，355：2733-2743.
|
| ［24］ |
Sawaki M，Ito Y，Akiyama F，et al.High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer.Breast Cancer，2006，13：172-178.
|
| ［25］ |
Johnston S，Trudeau M，Kaufman B，et al.Phase II study of predictive biomarker pro？les for response targeting human epidermal growth factor receptor 2（HER-2）in advanced inflammatory breast cancer with lapatinib monotherapy.J Clin Oncol，2008，26：1066-1072.
|
| ［26］ |
Ito Y，Tokudome N，Sugihara T，et al.Does lapatinib，a small-molecule tyrosine kinase inhibitor，constitute a breakthrough in the treatment of breast cancer？Breast Cancer，2007，14：156-162.
|